Other analysts also recently issued research reports about the company. BidaskClub upgraded TherapeuticsMD from a strong sell rating to a sell rating in a research report on Friday, February 9th. Noble Financial restated a buy rating on shares of TherapeuticsMD in a research report on Thursday, February 22nd. Deutsche Bank set a $9.00 target price on TherapeuticsMD and gave the stock a buy rating in a research report on Wednesday, December 20th. Finally, Cantor Fitzgerald restated a buy rating and issued a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. TherapeuticsMD has an average rating of Buy and an average target price of $14.50.
TXMD stock opened at $4.96 on Wednesday. The company has a market capitalization of $1,120.95, a PE ratio of -13.05 and a beta of 1.36. TherapeuticsMD has a twelve month low of $3.50 and a twelve month high of $8.30.
Hedge funds have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. lifted its position in TherapeuticsMD by 26.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock valued at $756,000 after purchasing an additional 30,030 shares during the last quarter. Swiss National Bank lifted its position in TherapeuticsMD by 12.3% in the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock valued at $1,533,000 after purchasing an additional 31,800 shares during the last quarter. Bank of New York Mellon Corp lifted its position in TherapeuticsMD by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock valued at $136,894,000 after purchasing an additional 2,985,846 shares during the last quarter. GSA Capital Partners LLP bought a new stake in TherapeuticsMD in the third quarter valued at approximately $528,000. Finally, Greenwood Capital Associates LLC lifted its position in TherapeuticsMD by 25.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 74,268 shares of the company’s stock valued at $449,000 after purchasing an additional 15,300 shares during the last quarter. Hedge funds and other institutional investors own 73.27% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.